Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech, Inc. (symbol: NKGN) is a progressive biotechnology company dedicated to developing cutting-edge cell therapies aimed at combating neurodegenerative and oncological diseases. The company’s central focus revolves around utilizing activated NK cells, which form a part of the human innate immune response system. These cells have the remarkable ability to selectively identify and eliminate abnormal or diseased cells.
NKGen Biotech’s innovative approach is anchored in a proprietary manufacturing and cryopreservation process that produces SuperNK™ (SNK) cells. These cells exhibit significantly enhanced activity compared to the original population of NK cells. Enhanced parameters include increased cytotoxicity, cytokine production, and activating receptor expression, based on detailed in vitro experiments conducted by NKMAX. One of the notable advantages of SNK cells is their ability to be produced in large quantities and preserved cryogenically without losing their high levels of cytotoxicity.
Recently, NKGen Biotech has achieved significant milestones with its SNK01 trial. Additional Phase 1 data point to clinical activity regarding cognitive function in patients with advanced Alzheimer’s disease, alongside previously disclosed positive effects on amyloid protein and neuroinflammation biomarkers. Dr. Jesse Carr, MD, Medical Director of Behavioral Research Specialists, LLC, has expressed optimism about the trial, highlighting the absence of treatment-related adverse events and noting apparent improvements in patients' cognitive function, daily living activities, and overall quality of life.
For investors and stakeholders, NKGen Biotech represents a beacon of innovation in the biotechnology sector, with its unique approach to developing cell therapies that could potentially redefine the treatment landscape for challenging diseases like Alzheimer’s and various cancers. The company’s robust pipeline, strategic partnerships, and ongoing clinical trials position it as a key player in advancing medical science and therapeutic solutions.
For the latest updates and detailed information, visit the NKGen Biotech website.
NKGen Biotech (Nasdaq: NKGN) has been selected as the preferred stalking horse bidder for NKMax in its court-managed rehabilitation process in South Korea. The proposal includes up to $18 million in committed funding from a third-party investor. Upon closing, expected in 1Q 2025, NKGen would secure global IP rights for troculeucel and other proprietary technologies. This acquisition would allow NKGen and partners to commercialize troculeucel in markets where NK cell therapy is already legal, including Korea and Japan. NKMax currently holds a 25% equity stake in NKGen, and post-acquisition, NKGen and its financing partners expect to hold a majority stake in NKMax.
NKGen Biotech (Nasdaq: NKGN) received a notice from Nasdaq on November 20, 2024, stating non-compliance with listing rules due to delayed filing of Q3 2024 Form 10-Q. The delay stems from additional time needed for internal derivative securities valuation. Nasdaq granted a temporary exception until January 7, 2025, pending the Seoul Bankruptcy Court's decision on NKMax's rehabilitation and NKGen's proposal to acquire majority interest. The company must submit an updated compliance plan following the court's decision. The notice doesn't immediately affect NKGN's Nasdaq Global Market listing, and the company aims to file the Form 10-Q promptly.
NKGen Biotech presented Phase 1/2a trial data for troculeucel in Alzheimer's Disease at the CTAD Conference. The Phase 1 trial showed that troculeucel reduces several biomarkers detectable up to 10 years before dementia symptoms. In the Phase 1/2a trial, using the highest dose of 6 billion cells, all three treated subjects showed stable or improved cognitive function, with two subjects improving from moderate to mild disease after three months. The treatment demonstrated strong safety with no adverse reactions. The Phase 1 pilot trial showed 90% of evaluable subjects experienced stable or improved cognitive function, with reductions in neuroinflammation biomarkers.
NKGen Biotech Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company, has announced its upcoming presentation at the 16th World Stroke Congress (WSC 2024) in Abu Dhabi, UAE from October 23–26, 2024. The company will showcase results of troculeucel, their innovative natural killer cell therapeutic, in a poster format.
The e-poster, titled "Therapeutic potential of expanded SNK01 (activated autologous natural killer cells) post-stroke to reduce neuroinflammation, inflammation-mediated cell death, and damage," will be presented in two sessions:
- Free Communications 09: Health Services & Implementation of Stroke Care on October 25, 2024, 8:00 am – 9:30 am GST in Hall F
- Plenary 03: Plenary, Awards & Late Breaking on October 25, 2024, 10:00 am – 11:30 am GST in Hall A/Plenary
The poster will be available on NKGen's website after the presentation.
NKGen Biotech Inc. (Nasdaq: NKGN) announced upcoming poster presentations at the 17th Annual Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain from October 29 – November 1, 2024. The presentations will cover:
1. A final report of a Phase 1 dose escalation study and a preliminary report of the Phase 1 cohort in the follow-up Phase 1/2a study of troculeucel in Alzheimer's disease subjects.
2. Further biomarker analysis and implications for use in prevention of Alzheimer's disease using non-genetically modified natural killer cells (SNK01) with enhanced activity.
The posters will be presented during Poster Session 1 on October 29-30, 2024. Full abstracts will be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD).
NKGen Biotech (Nasdaq: NKGN) has announced promising interim data from the Phase 1 cohort of its Phase 1/2a clinical trial for troculeucel, an autologous enhanced NK cell therapy for moderate Alzheimer's disease (AD). Two out of three patients treated with the highest dose (6 billion cells) showed improved CDR-SB cognitive scores, upgrading from moderate to mild AD after just three months.
The company has also dosed the first patient in the Phase 2 cohort, continuing with the 6 billion cell dose. The Phase 2 trial will evaluate troculeucel's efficacy in a randomized, double-blind, placebo-controlled study with 30 moderate AD patients. NKGen has activated four clinical sites across North America and expects to increase enrollment soon.
NKGen Biotech (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in NK cell therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Paul Y. Song, MD, Chairman and CEO of NKGen, will deliver a virtual presentation and engage in one-on-one meetings with investors.
Key points:
- The virtual presentation will be available on-demand starting September 9, 2024, at 7:00 AM Eastern Time
- Registered participants can submit questions after the presentation
- A webcast of the pre-recorded presentation will be accessible on NKGen's website
- The webcast replay will be available for 90 days following the presentation
This event provides an opportunity for NKGen to showcase its innovative NK cell therapeutics and engage with potential investors.
NKGen Biotech (Nasdaq: NKGN) has received a standard notice from Nasdaq on August 20, 2024, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1). This is due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2024. The delay is partly attributed to recent changes in the company's independent registered public accounting firm and valuation firm.
NKGen has been given 60 calendar days, until October 21, 2024, to submit a plan to regain compliance. Nasdaq can grant an exception of up to 180 calendar days, until February 18, 2025. The notice has no immediate effect on the listing or trading of NKGen's common stock on the Nasdaq Global Market. The company is actively working to file the Form 10-Q promptly and regain compliance within the given timeframe.
NKGen Biotech presented new positive data on its SNK01 therapy for Alzheimer's disease at the 2024 AAIC. The study showed that SNK01, a cryopreserved autologous non-genetically modified NK cell product, can effectively reduce α-synuclein (α-syn) protein levels in the cerebrospinal fluid of Alzheimer's patients. This is significant as increased α-syn correlates with worse cognitive performance and is not targeted by current treatments.
Key findings include:
- 60% of patients showed decreased CSF α-syn levels
- 90% of patients demonstrated stable or improved cognitive function
- SNK01 also improved amyloid, tau, and neuroinflammatory markers
- The therapy was well-tolerated with no treatment-related adverse events
NKGen plans to expand investigation in a larger Phase II trial with higher doses and longer treatment duration.
NKGen Biotech (Nasdaq: NKGN) will present new biomarker data on its SNK01 therapy for Alzheimer's disease at the 2024 Alzheimer's Association International Conference. The poster presentation will showcase SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant as α-synuclein correlates with worse cognitive function. The presentation, titled 'Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function,' will be held on July 30, 2024. This data adds to previously disclosed Phase 1 results showing SNK01's positive effects on amyloid, tau, and neuroinflammation biomarkers in Alzheimer's patients.
FAQ
What is the current stock price of NKGen Biotech (NKGN)?
What is the market cap of NKGen Biotech (NKGN)?
What does NKGen Biotech, Inc. specialize in?
What are SuperNK™ (SNK) cells?
What recent achievements has NKGen Biotech accomplished?
Where can I find the latest news about NKGen Biotech?
Who is overseeing the clinical trials for NKGen Biotech?
Can SNK cells be produced in large quantities?
Does NKGen Biotech have any partnerships?
What is the focus of NKGen Biotech’s ongoing projects?
Have there been any adverse events reported in the SNK01 trials?
What therapeutic areas is NKGen Biotech targeting?
